A Hypothesis of the Dual-Route Physical Immunotherapy for Lymphoma: Mediastinal Immune Defense and Bone Marrow–Driven Systemic MRD Eradication

Contemporary oncology, particularly in the management of advanced and metastatic lymphoma, remains heavily reliant on molecular antagonistic strategies, including monoclonal antibodies and genetically engineered T cells. Despite initial successes, this approach faces diminishing returns attributable to receptor saturation kinetics and microenvironmental immune evasion. Departing from conventional molecular frameworks, I propose a novel therapeutic hypothesis grounded in fluid dynamics and cell biophysics. By re-engaging with the body's innate anatomical architecture and physical barriers, I introduce a "dual-route physical immunotherapy" paradigm predicated not on molecular interference but on biomechanical intervention. My hypothesis delineates two principal therapeutic routes. First, peripheral superficial lymph nodes—specifically those in the cervical, supraclavicular, and axillary regions—are conceptualized as terrestrial sentinel outposts. Through Physical In-situ Lymph-node Antigenization (PILA), immune effector cells are directionally mobilized to fortify the mediastinal compartment. Second, the rigid osseous cranium of the bone marrow is harnessed as a natural bioreactor. Here, an osmotic bio-communition (OBC) technique is applied to marrow-localized lesions, leveraging controlled osmotic gradients and cyclic negative-pressure shear forces to physically disrupt malignant cell membranes. This process releases a pure antigen reservoir (PAR) in situ, which, via native marrow metabolic pathways draining into the splenic vein, systemically engages the splenic circulatory immune axis. The core tenet of my strategy is physical ignition, immunological completion. This approach aims to achieve comprehensive eradication of systemic minimal residual disease (MRD) in lymphoma through a low-cost, openly accessible scientific framework, circumventing the pharmacological and financial limitations of current biologic therapies.